Balyasny Asset Management LLC Gritstone Bio, Inc. Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$0.62 - $2.35 $11,559 - $43,813
18,644 New
18,644 $11,000
Q3 2023

Nov 14, 2023
BUY
$1.19 - $2.26 $185,522 - $352,336
155,901 Added 8.28%
2,037,949 $3.51 Million
Q2 2023

Aug 14, 2023
SELL
$1.66 - $3.03 $815,030 - $1.49 Million
-490,982 Reduced 20.69%
1,882,048 $3.67 Million
Q1 2023

May 15, 2023
BUY
$2.13 - $3.74 $678,383 - $1.19 Million
318,490 Added 15.5%
2,373,030 $6.6 Million
Q4 2022

Feb 14, 2023
BUY
$2.17 - $3.92 $4.46 Million - $8.05 Million
2,054,540 New
2,054,540 $7.09 Million

Others Institutions Holding GRTS

# of Institutions
61
Shares Held
35.4M
Call Options Held
395K
Put Options Held
132K
View Full List

About Gritstone bio, Inc.

GRTS Quotes by TradingView
  • Ticker GRTS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,006,896
  • Market Cap $2.19M
  • Description
  • Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...
More about GRTS
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email